GlassScriptPhysician profile
Michael B Small
NPI 1811182199
$4,428.86
in general payments reported to CMS, 2019-2025
23 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $137 · 2021: $111 · 2022: $483 · 2023: $969 · 2024: $987 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,214 · Education: $89.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,213.59 |
| Education | $89.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,540.33 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $599.72 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $428.15 | 2022-2025 | |
| Celgene Corporation | $419.26 | 2022-2024 | Zeposia |
| Pfizer INC. | $344.11 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $156.96 | 2022-2025 | Rebyota |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.67 | 2019-2025 | Xifaxan |
| Janssen Scientific Affairs, LLC | $124.99 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $95.25 | 2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $92.07 | 2019-2024 | Entyvio |
| Celltrion USA INC. | $76.65 | 2024-2025 | Vegzelma, Zymfentra |
| Ardelyx, INC. | $68.01 | 2023-2025 | Ibsrela |
| Intuitive Surgical, INC. | $59.58 | 2025 | |
| Medtronic, INC. | $43.75 | 2022-2025 | Pillcam |
| Regeneron Healthcare Solutions, INC. | $41.78 | 2022-2025 | Dupixent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $41.43 | 2020-2025 | |
| Phathom Pharmaceuticals, INC. | $26.56 | 2025 | Voquezna |
| Lilly USA, LLC | $25.00 | 2025 | Omvoh |
| Daiichi Sankyo INC. | $22.82 | 2022 | |
| Steris Corporation | $20.16 | 2023 | |
| Intercept Pharmaceuticals, INC. | $19.90 | 2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $17.69 | 2019 | |
| Aimmune Therapeutics, INC. | $17.02 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Small listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.